Drug Trial Radar · NCT06716424
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jan 6, 2025
Primary completion
Jun 12, 2026
Study completion Jun 12, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.
Conditions
- Type 2 Diabetes
Interventions
iGlarLixi (insulin glargine/lixisenatide)Drug
iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs)Time frame: From Day 1 to Week 25
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 3560009
Bengaluru, India
Investigational Site Number : 3560007
Delhi, India
Investigational Site Number : 3560005
Hyderabad, India
Investigational Site Number : 3560006
Indore, India
Investigational Site Number : 3560011
Jaipur, India
Investigational Site Number : 3560003
Kanpur, India
Investigational Site Number : 3560001
Kolkata, India
Investigational Site Number : 3560008
Pune, India
Investigational Site Number: 3560013
Pune, India
Investigational Site Number : 3560014
Visakhapatnam, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.